Gilead(GILD) - 2024 Q3 - Quarterly Results

GILEAD SCIENCES ANNOUNCES THIRD QUARTER 2024 FINANCIAL RESULTS Product Sales Excluding Veklury Increased 7% Year-Over-Year to $6.8 billion Biktarvy Sales Increased 13% Year-Over-Year to $3.5 billion Oncology Sales Increased 6% Year-Over-Year to $816 million Foster City, CA, November 6, 2024 - Gilead Sciences, Inc. (Nasdaq: GILD) announced today its third quarter 2024 results of operations. "Gilead's third quarter results are the strongest of the year to date, with 7% year-over-year revenue growth, including ...